Last reviewed · How we verify

fluticasone/salmeterol

Hull University Teaching Hospitals NHS Trust · FDA-approved active Small molecule

fluticasone/salmeterol is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) Small molecule drug developed by Hull University Teaching Hospitals NHS Trust. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy. Also known as: Seretide, Advair Diskus, advair, Advair 250/50.

Fluticasone/salmeterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle.

Fluticasone/salmeterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic namefluticasone/salmeterol
Also known asSeretide, Advair Diskus, advair, Advair 250/50, fluticasone/salmeterol combination
SponsorHull University Teaching Hospitals NHS Trust
Drug classInhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA)
TargetGlucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhaseFDA-approved

Mechanism of action

Fluticasone propionate is an inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Salmeterol is a long-acting beta-2 adrenergic agonist (LABA) that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and lasting 12 hours. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about fluticasone/salmeterol

What is fluticasone/salmeterol?

fluticasone/salmeterol is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) drug developed by Hull University Teaching Hospitals NHS Trust, indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does fluticasone/salmeterol work?

Fluticasone/salmeterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle.

What is fluticasone/salmeterol used for?

fluticasone/salmeterol is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes fluticasone/salmeterol?

fluticasone/salmeterol is developed and marketed by Hull University Teaching Hospitals NHS Trust (see full Hull University Teaching Hospitals NHS Trust pipeline at /company/hull-university-teaching-hospitals-nhs-trust).

Is fluticasone/salmeterol also known as anything else?

fluticasone/salmeterol is also known as Seretide, Advair Diskus, advair, Advair 250/50, fluticasone/salmeterol combination.

What drug class is fluticasone/salmeterol in?

fluticasone/salmeterol belongs to the Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) class. See all Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) drugs at /class/inhaled-corticosteroid-long-acting-beta-2-agonist-combination-ics-laba.

What development phase is fluticasone/salmeterol in?

fluticasone/salmeterol is FDA-approved (marketed).

What are the side effects of fluticasone/salmeterol?

Common side effects of fluticasone/salmeterol include Tremor, Headache, Palpitations, Oral candidiasis, Hoarseness, Nervousness/anxiety.

What does fluticasone/salmeterol target?

fluticasone/salmeterol targets Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) and is a Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing